MedTech Showcase Series: LightIntegra Technology

LightIntegra’s first product, ThromboLUX, was introduced to the US market in late 2017 and is starting to make a splash – by using ThromboLUX to determine platelet activation status, hospitals are seeing unprecedented reductions in platelet use for blood cancer treatment. On Wednesday, March 28, 2018, LifeSciences BC held its MedTech Showcase Series: LightIntegra Technology where attendees learned more about how ThromboLUX helps hospitals allocate platelets for more effective use, and heard about its other applications in transfusion medicine and diagnostics.